Vietnam Accused Of Failing To Follow Law On Drug Import Pricing
This article was originally published in PharmAsia News
Executive Summary
Vietnam's regulation of imported drugs is suffering from lax management by the agencies responsible, leading to recent increases in the price of medicine. One of the core problems, according to the Ho Chi Minh City Health Department's deputy director, lies in the Drug Administration of Vietnam's failure to put wholesale and retail prices on its public list. The law requires drug importers to consider the cost, insurance and freight in determining the two types of prices submitted to the DAV. Deputy Director Pham Khanh Phong Lan said the agency lists only the overall CIF prices and does not break out the wholesale and retail prices as required. (Click here for more
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.